ARTICLE | Clinical News
AVX-470: Phase Ib started
March 4, 2013 8:00 AM UTC
Avaxia began a double-blind, placebo-controlled, international Phase Ib trial to evaluate 0.2, 1.6 and 3.5 g oral AVX-470 daily for 28 days in about 24 patients with active UC. ...